T. Rowe Price Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $474M | Sell |
1,432,748
-270,083
| -16% | -$91.9M | 0.05% | 260 |
|
|
2025
Q4 | $677M | Sell |
1,702,831
-97,463
| -5% | -$43.1M | 0.07% | 209 |
|
|
2025
Q3 | $821M | Sell |
1,800,294
-1,344,712
| -43% | -$548M | 0.09% | 185 |
|
|
2025
Q2 | $1.03B | Sell |
3,145,006
-360,162
| -10% | -$99.7M | 0.12% | 162 |
|
|
2025
Q1 | $946M | Buy |
3,505,168
+185,783
| +6% | +$47.7M | 0.12% | 176 |
|
|
2024
Q4 | $781M | Sell |
3,319,385
-132,448
| -4% | -$34.8M | 0.09% | 199 |
|
|
2024
Q3 | $949M | Sell |
3,451,833
-36,170
| -1% | -$9.42M | 0.11% | 176 |
|
|
2024
Q2 | $848M | Sell |
3,488,003
-197,750
| -5% | -$31.2M | 0.1% | 179 |
|
|
2024
Q1 | $551M | Buy |
3,685,753
+201,784
| +6% | +$33.7M | 0.07% | 259 |
|
|
2023
Q4 | $667M | Sell |
3,483,969
-441,035
| -11% | -$75.1M | 0.09% | 212 |
|
|
2023
Q3 | $695M | Buy |
3,925,004
+39,468
| +1% | +$7.53M | 0.1% | 199 |
|
|
2023
Q2 | $738M | Sell |
3,885,536
-87,340
| -2% | -$17.3M | 0.1% | 194 |
|
|
2023
Q1 | $796M | Sell |
3,972,876
-101,268
| -2% | -$21.3M | 0.12% | 180 |
|
|
2022
Q4 | $968M | Buy |
4,074,144
+353,538
| +10% | +$75.4M | 0.16% | 140 |
|
|
2022
Q3 | $745M | Sell |
3,720,606
-3,276,476
| -47% | -$625M | 0.12% | 166 |
|
|
2022
Q2 | $1.02B | Buy |
6,997,082
+202,916
| +3% | +$28.8M | 0.13% | 170 |
|
|
2022
Q1 | $1.11B | Buy |
6,794,166
+258,798
| +4% | +$39.4M | 0.11% | 188 |
|
|
2021
Q4 | $1.11B | Buy |
6,535,368
+661,133
| +11% | +$123M | 0.1% | 201 |
|
|
2021
Q3 | $1.11B | Buy |
5,874,235
+349,557
| +6% | +$65.6M | 0.1% | 201 |
|
|
2021
Q2 | $937M | Sell |
5,524,678
-50,535
| -0.9% | -$7.4M | 0.09% | 245 |
|
|
2021
Q1 | $787M | Sell |
5,575,213
-129
| -0% | -$19.4K | 0.08% | 261 |
|
|
2020
Q4 | $725M | Sell |
5,575,342
-439,509
| -7% | -$58.7M | 0.07% | 267 |
|
|
2020
Q3 | $876M | Sell |
6,014,851
-257,575
| -4% | -$36.6M | 0.1% | 211 |
|
|
2020
Q2 | $929M | Sell |
6,272,426
-15,334
| -0.2% | -$2.07M | 0.12% | 186 |
|
|
2020
Q1 | $684M | Buy |
6,287,760
+936,668
| +18% | +$108M | 0.11% | 200 |
|
|
2019
Q4 | $616M | Buy |
5,351,092
+467,438
| +10% | +$46.6M | 0.08% | 264 |
|
|
2019
Q3 | $393M | Buy |
4,883,654
+1,375,040
| +39% | +$109M | 0.06% | 320 |
|
|
2019
Q2 | $255M | Buy |
3,508,614
+25,025
| +0.7% | +$1.92M | 0.04% | 408 |
|
|
2019
Q1 | $326M | Sell |
3,483,589
-192,236
| -5% | -$16.1M | 0.05% | 346 |
|
|
2018
Q4 | $268M | Sell |
3,675,825
-524,930
| -12% | -$40.4M | 0.05% | 359 |
|
|
2018
Q3 | $368M | Sell |
4,200,755
-1,013,208
| -19% | -$102M | 0.05% | 339 |
|
|
2018
Q2 | $514M | Sell |
5,213,963
-7,355,371
| -59% | -$730M | 0.08% | 246 |
|
|
2018
Q1 | $1.5B | Buy |
12,569,334
+336,093
| +3% | +$43.3M | 0.24% | 93 |
|
|
2017
Q4 | $1.55B | Buy |
12,233,241
+3,668,358
| +43% | +$461M | 0.25% | 92 |
|
|
2017
Q3 | $1.01B | Buy |
8,564,883
+1,896,280
| +28% | +$162M | 0.17% | 136 |
|
|
2017
Q2 | $532M | Buy |
6,668,603
+2,500,634
| +60% | +$160M | 0.1% | 238 |
|
|
2017
Q1 | $214M | Buy |
4,167,969
+4,255
| +0.1% | +$197K | 0.04% | 418 |
|
|
2016
Q4 | $156M | Buy |
4,163,714
+138,306
| +3% | +$5.79M | 0.03% | 476 |
|
|
2016
Q3 | $273M | Buy |
4,025,408
+29,266
| +0.7% | +$2.06M | 0.05% | 335 |
|
|
2016
Q2 | $222M | Buy |
3,996,142
+2,712,060
| +211% | +$171M | 0.05% | 385 |
|
|
2016
Q1 | $80.6M | Buy |
1,284,082
+46,237
| +4% | +$3.07M | 0.02% | 610 |
|
|
2015
Q4 | $117M | Sell |
1,237,845
-82,350
| -6% | -$7.64M | 0.02% | 521 |
|
|
2015
Q3 | $106M | Sell |
1,320,195
-391,099
| -23% | -$43.5M | 0.02% | 556 |
|
|
2015
Q2 | $205M | Buy |
1,711,294
+449,690
| +36% | +$53.7M | 0.04% | 439 |
|
|
2015
Q1 | $132M | Buy |
1,261,604
+19,578
| +2% | +$1.98M | 0.03% | 537 |
|
|
2014
Q4 | $120M | Sell |
1,242,026
-1,942,036
| -61% | -$180M | 0.03% | 567 |
|
|
2014
Q3 | $249M | Sell |
3,184,062
-67,971
| -2% | -$4.38M | 0.05% | 383 |
|
|
2014
Q2 | $205M | Sell |
3,252,033
-342,698
| -10% | -$20.4M | 0.04% | 429 |
|
|
2014
Q1 | $241M | Sell |
3,594,731
-219,314
| -6% | -$17M | 0.05% | 393 |
|
|
2013
Q4 | $245M | Sell |
3,814,045
-422,690
| -10% | -$25.2M | 0.06% | 382 |
|
|
2013
Q3 | $271M | Buy |
4,236,735
+1,928,635
| +84% | +$96.1M | 0.07% | 333 |
|
|
2013
Q2 | $71.6M | Buy |
+2,308,100
| New | +$61.4M | 0.02% | 673 |
|
Other funds holding ALNY
VPM
VCM
T. Rowe Price Associates's ALNY Position: Q1 2026 in Review
T. Rowe Price Associates reduced its Alnylam Pharmaceuticals (ALNY) stake by 16% in Q1 2026, selling an estimated $91.9M and leaving 1,432,748 shares worth $474M. The position accounts for 0.05% of the portfolio, ranked #260.
T. Rowe Price Associates first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.55B in Q4 2017. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- T. Rowe Price Associates held 1,432,748 shares of Alnylam Pharmaceuticals worth $474M as of Q1 2026.
- T. Rowe Price Associates sold 270,083 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $91.9M.
- Alnylam Pharmaceuticals made up 0.05% of T. Rowe Price Associates's portfolio in Q1 2026, its #260 holding.
- T. Rowe Price Associates first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Alnylam Pharmaceuticals position peaked at $1.55B in Q4 2017.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.